Understanding Parathyroid Hormone and Its Function

Parathyroid hormone (PTH) is a critical regulator of calcium and phosphate metabolism in the human body. Produced by the parathyroid glands, this hormone maintains the delicate balance of calcium in our bloodstream, bones, and other tissues.

When natural PTH production is insufficient or when bone density needs to be increased, synthetic parathyroid hormone injections become necessary medical interventions. These medications mimic the action of natural PTH by stimulating bone formation, increasing intestinal calcium absorption, and enhancing calcium reabsorption in the kidneys.

The two main clinical applications for PTH injections are:

  • Hypoparathyroidism: A condition where the body produces insufficient amounts of parathyroid hormone
  • Osteoporosis: A bone disease characterized by decreased bone density and increased fracture risk

Unlike many other hormone replacement therapies, PTH injections are typically administered daily via subcutaneous injection, making the selection of an appropriate brand and delivery system particularly important for patient compliance and treatment success.

Teriparatide: The Pioneer PTH Medication

Teriparatide, sold under the brand name Forteo (Eli Lilly), represents the first recombinant parathyroid hormone analog approved for medical use. This medication contains the active fragment of human parathyroid hormone (PTH 1-34) and has been a cornerstone in osteoporosis treatment since its FDA approval in 2002.

Forteo comes in a prefilled pen delivery system containing 28 daily doses (600 mcg/2.4 mL) and requires refrigeration. The recommended dose is 20 mcg administered once daily as a subcutaneous injection in the thigh or abdominal wall.

Clinical studies have demonstrated that Forteo can increase bone mineral density and reduce the risk of vertebral and non-vertebral fractures in postmenopausal women with osteoporosis. However, treatment duration is typically limited to 24 months due to safety considerations.

In recent years, biosimilar versions of teriparatide have entered the market, including:

  • Terrosa (Gedeon Richter)
  • Movymia (STADA Arzneimittel)
  • Bonsity (Alvogen)

These alternatives offer comparable efficacy to the original Forteo while potentially providing more accessible options for patients based on cost and availability in different regions.

Abaloparatide: The Next Generation Option

Abaloparatide, marketed under the brand name Tymlos (Radius Health), represents a newer addition to the parathyroid hormone-related protein (PTHrP) analog category. Approved by the FDA in 2017, abaloparatide selectively activates the PTH type 1 receptor, stimulating bone formation with potentially fewer side effects than earlier options.

Tymlos is supplied as a prefilled pen that delivers 30 daily doses of 80 mcg abaloparatide in 1.5 mL solution. Like other PTH medications, it requires refrigeration when not in use but can remain at room temperature for up to 30 days after first use.

What distinguishes abaloparatide from teriparatide is its molecular structure and receptor binding profile. Studies suggest that Tymlos may offer:

  • Greater increases in bone formation compared to bone resorption
  • Potentially lower risk of hypercalcemia
  • Significant reduction in vertebral and nonvertebral fracture risk

The recommended treatment course for Tymlos is 18 months, followed by antiresorptive therapy to maintain bone density gains. This medication has become an important alternative for patients who cannot tolerate or have not responded adequately to teriparatide treatment.

PTH (1-84): Full-Length Parathyroid Hormone Products

Unlike the partial PTH analogs discussed previously, full-length parathyroid hormone (PTH 1-84) medications contain the complete 84-amino acid sequence of natural human parathyroid hormone. The primary brand in this category is Natpara (Takeda Pharmaceuticals), which received FDA approval in 2015 specifically for managing hypocalcemia in patients with hypoparathyroidism.

Natpara is supplied in a dual-chamber glass cartridge containing 14 doses, which must be reconstituted before use with the specialized Q-Cliq delivery device. Available in multiple dosage strengths (25, 50, 75, and 100 mcg), this medication allows for dose titration based on individual patient needs.

The administration of Natpara differs from osteoporosis-focused PTH analogs:

  • It is typically given once daily as an adjunct to calcium and vitamin D supplementation
  • Dosing aims to maintain serum calcium within the lower half of the normal range
  • Treatment is often long-term due to the chronic nature of hypoparathyroidism

It's worth noting that Natpara has experienced supply challenges in recent years due to a recall related to rubber particulate concerns in the product delivery system. This has highlighted the need for alternative management strategies for patients with hypoparathyroidism during periods of limited availability.

Emerging Brands and Future Developments

The field of parathyroid hormone therapies continues to evolve with several promising developments on the horizon. Researchers and pharmaceutical companies are focusing on creating improved formulations with enhanced efficacy, convenience, and safety profiles.

Among the notable developments in this space:

  • TransCon PTH (Ascendis Pharma): A long-acting prodrug of PTH (1-34) designed to provide sustained release over one week, potentially improving treatment adherence for hypoparathyroidism patients
  • PTH-CBD: An investigational oral formulation of PTH combined with a carrier molecule to enable intestinal absorption, potentially eliminating the need for injections
  • EB613 (Entera Bio): An oral PTH (1-34) tablet leveraging proprietary technology to enhance bioavailability

These innovations address key challenges in current PTH therapy:

Non-injectable administration routes would significantly improve patient convenience and potentially adherence. Extended-release formulations could reduce injection frequency from daily to weekly or monthly. Targeted delivery systems might allow for more precise control of calcium metabolism with fewer side effects.

As clinical trials progress, patients may soon have access to these next-generation parathyroid hormone products that could transform the management of both osteoporosis and hypoparathyroidism.